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Lung cancer has been the leading cause of cancer deathamong men in the United States and throughout the world
for years, and since 1988, it has become the number one
cause of cancer death among women. More women die
annually of lung cancer than of breast, ovarian, and uterine
cancers combined. More than 81,000 new cases of lung
cancer were diagnosed in American women in 2006.1 It is
estimated that 72,000 women will die of progressive lung
cancer, accounting for 26% of all cancer deaths in women.1
Lung cancer, rare in women in the early 1900s, has
progressively reached epidemic proportion. In the past 30
years, there has been a fourfold increase in lung cancer,
referred to as a “contemporary epidemic.”2 The increase in
the incidence of lung cancer among women is primarily the
result of an increase in their tobacco use. Just as in men, most
(85–90%) lung cancers among women are considered to be
caused by smoking. Women began smoking in significant
numbers in the 1940s, and although overall smoking rates
have declined since reaching a peak in the 1970s, the current
prevalence of smoking among women is still alarmingly high
(22% in 2004).3
There is considerable controversy over the relative risk
(RR) for lung cancer among women versus men at any given
level of tobacco exposure. Several case control studies from
the 1990s have argued that women are more susceptible to the
carcinogens in cigarette smoke than men. Recently, Henschke
and Miettinene evaluated the absolute risk for lung cancer in
a high-risk population of women and men older than 40 years
and with at least a 10-pack-year tobacco history who under-
went baseline computed tomography (CT) screening for lung
cancer. After adjusting for age and smoking history, the risk
for lung cancer among women versus men was 2.7.4 How-
ever, an analysis of the Nurses’ Health Study of more than
60,000 women and the Health Professionals Follow-up Study
of more than 25,000 men failed to find an increased lung
cancer risk among women.5 Regardless of sex differences in
the RR of lung cancer among smokers, lung cancer seems to
be a different disease in women. Moreover, multiple studies
suggest that women may be more susceptible than men to the
carcinogenic effects of cigarette smoke as a result of genetic,
metabolic, and hormonal factors.
GENETIC FACTORS
Tobacco smoke contains more than a hundred diverse
mutagens and carcinogens that exert their effects through
both gene mutations and formation of DNA adducts. Two
classes of enzymes play a crucial role in the metabolism of
tobacco-related carcinogens: phase I and II detoxifying en-
zymes. Whereas phase I enzymes (i.e., cytochrome P450,
monooxygenases) activate carcinogens to reactive intermedi-
ates, their action is balanced by phase II enzymes, which
serve to convert these same reactive intermediates (i.e., reac-
tive oxygen species) into inactive conjugates. Women smok-
ers have an increased expression of the CYP1A1 gene in the
lung compared with men smokers, resulting in an increased
level of DNA adducts and thus in a decreased ability to
detoxify tobacco carcinogens.6 Increased CYP1A1 enzyme
expression may be the result of induction by hormones,
notably estrogen. The most common polymorphism in phase
II detoxification enzymes is the glutathione S-transferase M1
(GSTM1) null genotype, which is present in 40% to 60% of
the general population because of a gene deletion.7 Although
non-expression (null phenotype) does not seem to increase
risk by itself, a null phenotype combined with high CYP1A1
expression was shown to increase the risk ratio for lung
cancer among women versus men (OR, 6.54 vs 2.36).8,9
Another area of investigation involves genetic differences in
the gastrin-releasing peptide receptor (GRPR) gene that is
located on the X chromosome near a cluster of genes that
escape X-inactivation. Therefore, women can have two ac-
tively transcribed alleles of the GRPR gene, compared with
only one in men. Shriver et al. reported that GRPR mRNA is
expressed more frequently in women than in men non-
smokers (55% vs 0%), and it is detected at lower levels of
tobacco exposure among smokers in women than in men
(75% vs 20%).10 The same group also showed increased
expression of the GRPR gene when human airway cells were
exposed to estrogen, suggesting that GRPR could also be
regulated by the hormone.10
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MOLECULAR FACTORS
A tumor suppressor gene that is often mutated in lung
cancer is p53 (in 90% of small-cell lung cancers [SCLC] and
40–70% of non-small cell lung cancers [NSCLCs]) with G:C
¡ T:A transversion being the dominant mutation. Kure et al.
found a higher frequency of this mutation in the p53 gene
and, consequently, a higher average DNA adduct level in the
lung tumors of women and men. However, the level of
exposure to carcinogens from cigarette smoking was lower
among women (mean 23 pack-years) than among men (mean
39 pack-years).11 Of the Ras family of proto-oncogenes,
K-ras is the most frequently affected gene. As in the p53 gene
mutation, the formation of DNA adducts secondary to the
effects of smoking seems to play a pivotal role. K-ras gene
mutations have been found more often in female patients with
lung cancer (26%) who were smokers than among male
smokers with lung cancer (17%).12 In most studies, Ras
mutations are predominantly associated with adenocarci-
noma, and Nelson and colleagues suggest that cigarette
smoking induces K-ras mutations and that the resultant clones
could be further expanded by a second event possibly involv-
ing the growth-promoting effects of hormones (like estro-
gens) that may be specific for the adenocarcinoma histology.
HORMONAL FACTORS
The role of hormones, particularly estrogen, as a risk
factor for the development of lung cancer among women is
another area of vigorous investigation because the most
obvious biological differences between men and women are
hormonal. Estrogens contribute to differentiation and matu-
ration in the normal lung and stimulate growth and progres-
sion of lung tumors. These biological effects are mediated by
estrogen receptors with ER expressed at a higher level in
lung cancer, as demonstrated by Stabile et al.13 A 17-fold
increase in cellular proliferation after -estradiol treatment
was observed in lung cancer-derived cell lines, as opposed to
only a 3.8-fold increase in normal lung fibroblasts. Based on
these data and on preclinical data showing an inverse cross-
talk between the EGFR and ER pathways, at ASCO 2005,
Traynor et al. presented the preliminary results of a combi-
nation treatment with fulvestrant, a drug able to block estra-
diol-stimulated tumor growth in NSCLC cell lines, and ge-
fitinib, an EGFR tyrosine kinase inhibitor in postmenopausal
women with advanced NSCLC. The combination was well
tolerated with disease activity. Correlative studies showed no
relation between the amount of ER, ER, or EGFR expres-
sion in the tumor and response to treatment.14 Conflicting
data exist about hormone replacement therapy (HRT) in
women. Using case-control data, Taioli and Wynder showed
that early menopause is associated with a decreased risk of
adenocarcinoma in women, whereas the use of HRT and its
interaction with smoking leads to an increased risk of lung
cancer (ORs, 1.7 and 32.4 in non-smokers and smokers,
respectively).15 Some data suggest that HRT may actually
exert a protective effect, with the risk of lung cancer decreas-
ing with length of use. A study from MD Anderson reported
that tobacco and estrogen interact in women who currently
smoke, whereas HRT seems to have more than a protective
effect for never or former smokers.16 All these studies are
limited by the lack of information on the exact dose and
duration of HRT use in each patient. Further research on this
topic is needed and should include a detailed gynecological
history and use of all forms of hormone therapy to obtain a
better understanding of the role of estrogens and progestins in
the pathogenesis of lung cancer.
CLINICAL IMPLICATIONS
Multiple population-based studies of patients present-
ing with all stages of lung cancer have demonstrated that the
female sex is an independent predictor of survival in multi-
variate analyses. By the mid-1970s, Edmonson et al. had
already reported that women with chemotherapy-treated ad-
enocarcinoma or with inoperable SCLC survived longer than
men.17 A Polish population-based study of 20,561 patients in
the cancer registry from 1995 to 1998 showed men to have a
1.15 RR of death (p 0.001).18 In this series, female patients
were younger (age50 years, 23.3% vs 12%; p 0.001) and
more likely to have adenocarcinoma (21.6% vs 9.6%; p 
0.001) and SCLC (26.6% vs 19.9%; p  0.001). More
women than men were non-smokers (18.8% vs 2.4%; p 
0.001). A retrospective review of 7,553 patients treated for
NSCLC between 1974 and 1998 at a single institution found
an overall median survival of 12.4 months for women and
10.3 months for men (p  0.001).19 The survival advantage
was present at all stages. In addition to retrospective popu-
lation-based studies, prospective cohort studies also found
female sex to be an independent predictor of survival. Visbal
et al.’s study of patients with NSCLC treated at a single
institution from 1997 to 2000 found male sex to be an
independent predictor of poor prognosis, with an RR of death
of 1.2.20 In addition, tumor grade was also found to be an
independent predictor of prognosis, a sort of surrogate for
underlying genetic differences, which are ultimately respon-
sible for differences in outcome between men and women.
NSCLC: EARLY-STAGE DISEASE
In localized NSCLC (i.e., stage I or II), women expe-
rience superior survival after either surgical resection or
radiation as single modalities. Minami et al. evaluated the
results of 1242 consecutive operative interventions for lung
cancer and observed that even if complete resection was
achieved less often in women than in men (79.6% vs 85.2%),
women who underwent a complete resection, especially
women older than 60 years, survived longer (5- and 10-year
survival rates were 69% and 51%, respectively) than their
male counterparts.21 Female sex has also been associated with
superior outcome in patients treated with radiotherapy. A
better outcome for women than for men (11.4 vs 9.9 months,
respectively) was observed when more than 1900 patients,
treated in nine Radiation Therapy Oncology Group trials
between 1983 and 1994 with thoracic radiation with or
without chemotherapy (cisplatin-based), were reviewed by
Werner-Wasik et al.22 Interestingly, the preliminary results of
an analysis of 91 patients (21 female) with curatively resected
NSCLC demonstrated that several prognostic markers
seemed to be sex-specific.23 High levels of ERCC1, Her2, and
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RXR predicted better survival among women but not men. In
men, low cyclooxygenase-2 expression and high ornithine
decarboxylase expression predicted better survival, but they
were not predictive in women. This study is limited by its
small numbers and requires validation. However, it serves to
further emphasize the potential importance of sex in analyz-
ing outcomes as well as potential predictive and prognostic
markers.
NSCLC: LOCALLY ADVANCED AND
METASTATIC DISEASE
Studies in locally advanced disease evaluating differ-
ential outcomes between the sexes are few; however, some
reports have shown that women fare better than men when
treated with radiation therapy with or without chemotherapy.
Several large databases consisting exclusively of patients
with advanced NSCLC also found female sex to be an
independent predictor of survival. Albain et al. reviewed the
2531 patients enrolled in 13 SWOG trials of therapeutic
interventions in advanced NSCLC conducted between 1974
and 1987 and found female sex to be a strong independently
favorable factor for survival with a risk ratio of 0.77.24 The
median survival ratio for women versus men was 5.7 versus
4.8, with 1-year survival rates of 19% versus 14% (p  0.01
for survival comparisons within each category). Identical
results were reported by the European Lung Cancer Working
Party (ELCWP) in a review of 1052 patients with locally
advanced or metastatic NSCLC treated with cisplatinum-
based chemotherapy from 1980 to 1991.25 Female sex was
one of the eight variables significantly associated with supe-
rior survival. In second-line therapy, female sex has also
shown to be predictive of improved outcomes. In several
studies, epidermal growth factor receptor tyrosine kinase
inhibitors, such as gefitinib and erlotinib, had better efficacy
in women. Two large phase II trials of gefitinib monotherapy,
the IRESSA Dose Evaluation in Advanced Lung Cancer
(IDEAL) 1 and IDEAL 2 studies, evaluated the agent in
pretreated NSCLC.26,27 Retrospective subset analysis demon-
strated that female sex, adenocarcinoma (in particular, bron-
chiolalveolar histology), and non-smoking status were pre-
dictors of response.27,28 Response rates to epidermal growth
factor receptor inhibitors have been associated with mutations
in the tyrosine kinase domain of the epidermal growth factor
receptor. The improved prognosis observed for women may
be secondary to differences in frequency of the underlying
activating mutations: 20% in women versus 9% in men.29,30
Caution should be taken in the interpretation of these results
because neither trial was randomized, and the factors ana-
lyzed were retrospectively selected. Similar results have been
obtained with erlotinib, a chemically similar agent recently
approved for second- and third-line therapy of advanced
NSCLC.
SCLC
Studies of SCLC also show a superior outcome for
women. The NCI-Navy Medical Oncology Branch analyzed
the results of four consecutive prospective trials and found
that women had superior survival compared with men, with
the most pronounced advantage for patients surviving longer
than 2.5 years, which implies that the chance of cure is higher
among women than men.31 A total of 2580 patients enrolled
in 10 SWOG SCLC trials including both limited disease and
extensive-stage disease were analyzed for prognostic indica-
tors.32 In the six SWOG LD trials, female sex predicted the
best outcome with a median survival of 24.4 months among
women versus 17.7 months among men. However, in the
SWOG ED trials, there was a non-significant trend toward
superior survival in women. A retrospective review of out-
comes and toxicities of four trials of SCLC was performed by
the National Cancer Institute of Canada.33 At multivariate
analysis, women were found to have increased toxicity with
chemotherapy, and significantly increased treatment delays (2
or more weeks; p  0.022) were also observed. Despite the
delays, women had an increased overall response rate (80.3%
for women vs 66.9% for men; p  0.0001) and median
survival (1.31 years for women and 0.91 for men; p 
0.0001).
Improved survival of women with lung cancer (NSCLC
and SCLC) needs to be correctly evaluated in the light of sex
migration. From 1990 to 2003, an increase in the number of
new cases of lung cancer among women was reflected in the
proportion of women participants in clinical trials. In the
same period, a stable number of men were diagnosed as
having lung cancer. Sex migration can certainly confuse even
carefully designed clinical trials, suggesting that future trials
may benefit from stratification by sex.
CONCLUSIONS
Approximately 85% to 90% of lung cancer cases can be
ascribed to smoking. It is clear that the most effective form of
intervention aimed at stopping the lung cancer epidemic in
both women and men is to reduce smoking rates to zero. In
this context, further support should be given to campaigns of
smoking prevention in youngsters (especially girls). Until
now, early detection of lung cancer, even among former-
smoking women, has only been performed in two prospective
studies of lung cancer screening. There are very clear differ-
ences in the biology, natural history, and response to therapy
between men and women with this disease, and emerging
literature provides a biological basis for these differences.
However, because most of the literature on this topic is
retrospective, prospective evaluations of these differences,
particularly as they apply to clinical practice, are required. No
definitive statement can be made about the outcome of
treatment for lung cancer among women compared with men.
For current clinical practice, there is no area in which sex
enters into the equation in patient management. Even if the
value of the epidermal growth factor receptor tyrosine kinase
inhibitors (gefitinib, erlotinib) is clearly most pronounced
among never-smoking women, this approach will need to be
confirmed by prospective clinical trials. Sex-based clinical
trials taking sex-associated differences into account are war-
ranted to provide new options for patient treatment and to
affect clinical practice.
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